Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
CONCLUSION: Patients with mHSPC who received abiraterone acetate with ADT had better PFS and less toxicity compared to those receiving docetaxel with ADT. A trend towards superior OS and less treatment-related deaths was also observed, yet statistically non-significant. In view of lacking clear OS advantage, the choice between docetaxel and AA should include a discussion with the patient about potential toxicities and impact on quality of life of each regimen.
PMID: 29490505 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Databases & Libraries | Docetaxel | Hormones | Prostate Cancer | Research | Statistics | Study | Taxotere | Toxicology